コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ions of allogeneic bone marrow or peripheral blood stem cell transplantation.
2 er allogeneic marrow or filgrastim-mobilized blood stem cell transplantation.
3 py, whole-brain radiotherapy, and peripheral blood stem cell transplantation.
4 risk factors for acute GVHD after allogeneic blood stem cell transplantation.
5 f graft-versus-host disease after peripheral blood stem cell transplantation.
6 s undergoing autologous marrow or peripheral blood stem cell transplantation.
7 rwent high-dose chemotherapy with peripheral blood stem cell transplantation.
8 ent infection in encephalitis following cord blood stem cell transplantation.
9 RIC unrelated adult donor or umbilical cord blood stem cell transplantation.
10 who would have been eligible for peripheral-blood stem-cell transplantation.
11 ns of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
12 chronic GVHD was significantly higher after blood stem cell transplantation (1-year probability [95%
14 tion to hospital discharge was 23 days after blood stem cell transplantation and 28 days after bone m
15 y JC papovavirus after autologous peripheral blood stem cell transplantation and a case each of cytom
16 ute to inferior platelet recovery after cord blood stem cell transplantation and may underlie ineffic
17 roid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in
19 ith autologous and allogeneic bone marrow or blood stem cell transplantation appear to induce a prolo
20 ho underwent autologous marrow or peripheral-blood stem-cell transplantation at our institution betwe
22 rticularly high-dose therapy with peripheral blood stem cell transplantation, can achieve complete re
23 owed by autologous bone marrow or peripheral-blood stem-cell transplantation for patients with follic
24 nic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical si
25 c granulomatous disease underwent peripheral-blood stem-cell transplantation from an HLA-identical si
26 d recovery of hematopoiesis after allogeneic blood stem cell transplantation has been attributed to t
27 emotherapy followed by autologous peripheral blood stem cell transplantation (HDM/SCT) can produce he
28 halan chemotherapy and autologous peripheral blood stem cell transplantation (HDM/SCT) have been deve
29 ensive intravenous melphalan with autologous blood stem-cell transplantation improves the nephrotic s
30 0(4) T cells/kg) nonmyeloablative peripheral blood stem cell transplantation in children and young ad
31 ymph node irradiation (TMLI), for peripheral blood stem cell transplantation, in patients with advanc
32 ensive intravenous melphalan with autologous blood stem-cell transplantation induces remission of the
34 NCA (131)I-MIBG with autologous peripheral blood stem cell transplantation is feasible at 666 MBq/k
36 oplatin and etoposide followed by peripheral-blood stem-cell transplantation or autologous bone marro
37 tution with high-dose therapy and peripheral blood stem cell transplantation (PBSCT) followed by Id i
39 oved response rates observed with peripheral blood stem cell transplantation (PBSCT) in patients with
42 icenter phase III trial comparing peripheral blood stem cell transplantation (PBSCT) to bone marrow t
43 is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but the selecti
46 high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplantation (PBSCT) at Indiana Unive
47 disease (GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when compared wi
49 us bone marrow transplantation or peripheral blood stem-cell transplantation (referred to as high-dos
51 dministration of filgrastim after allogeneic blood stem cell transplantation shortens the time to neu
52 chronic GVHD after HLA-identical allogeneic blood stem cell transplantation, that clinical factors m
53 on the topic of cord blood banking and cord blood stem cell transplantation was conducted for this t
54 sus-host disease after allogeneic peripheral blood stem-cell transplantation who had severe refractor
55 ompared results of 288 HLA-identical sibling blood stem cell transplantations with results of 536 HLA
56 (2) intravenously) and autologous peripheral blood stem cell transplantation, with marked improvement
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。